Lipoprotein(a) Reduction in Persons with Cardiovascular Disease

Tsimikas, Sotirios, Karwatowska-Prokopczuk, Ewa, Gouni-Berthold, Ioanna, Tardif, Jean-Claude, Baum, Seth J., Steinhagen-Thiessen, Elizabeth, Shapiro, Michael D., Stroes, Erik S., Moriarty, Patrick M., Nordestgaard, Børge G., Xia, Shuting, Guerriero, Jonathan, Viney, Nicholas J., O’Dea, Louis, Witztum, Joseph L.·2020·New England Journal of Medicine
DOI 10.1056/nejmoa1905239

Cited by (1,001)

Items 301–400 of 1,001

  1. Daring to dream: Targeting lipoprotein(a) as a causal and risk-enhancing factor
    Marlys L. Koschinsky, Erik S.G. Stroes, Florian Kronenberg · 2023 · Pharmacological Research
  2. Lipoprotein(a): Just an Innocent Bystander in Arterial Hypertension?
    Gabriele Brosolo, Andrea Da Porto, Stefano Marcante, Alessandro Picci, Filippo Capilupi, Patrizio Capilupi, Luca Bulfone, Antonio Vacca, Nicole Bertin, Cinzia Vivarelli et al. · 2023 · International Journal of Molecular Sciences
  3. Lipoprotein(a): Expanding our knowledge of aortic valve narrowing
    Amer Youssef, Justin R. Clark, Marlys L. Koschinsky, Michael B. Boffa · 2020 · Trends in Cardiovascular Medicine
  4. Lipoprotein(a) Reduction in Persons with Cardiovascular Disease
    Charles Joseph Ferro, Pantelis Sarafidis, Alberto Ortíz · 2020 · New England Journal of Medicine
  5. Particle Number and Characteristics of Lipoprotein(a), LDL, and apoB
    Sotirios Tsimikas, Vera Bittner · 2024 · Journal of the American College of Cardiology
  6. Autotaxin inhibition attenuates the aortic valve calcification by suppressing inflammation-driven fibro-calcific remodeling of valvular interstitial cells
    Dohee Yoon, Bongkun Choi, Ji-Eun Kim, Eun‐Young Kim, Soo-Hyun Chung, Hyo-Jin Min, Yoolim Sung, Eun‐Ju Chang, Jae‐Kwan Song · 2024 · BMC Medicine
  7. Worldwide Increasing Use of Nonfasting Rather Than Fasting Lipid Profiles
    Anne Langsted, Børge Grønne Nordestgaard · 2024 · Clinical Chemistry
  8. Lp(a): A Rapidly Evolving Therapeutic Landscape
    Khalil Anchouche, George Thanassoulis · 2024 · Current Atherosclerosis Reports
  9. Evolution of antisense oligonucleotides: navigating nucleic acid chemistry and delivery challenges
    Ruchi Ruchi, Govind Mukesh Raman, Vikas Kumar, Raman Bahal · 2024 · Expert Opinion on Drug Discovery
  10. Lipoprotein(a) – From Biomarker to Therapy: A Review for the Clinician
    Mawra Jha, Inbar Raber, Eli V. Gelfand · 2025 · The American Journal of Cardiology
  11. Pelacarsen: Mechanism of action and Lp(a)-lowering effect
    Harpreet Singh Bhatia, Archna Bajaj, Sascha N. Goonewardena, Patrick M. Moriarty · 2025 · Journal of clinical lipidology
  12. Precision cardiovascular medicine: shifting the innovation paradigm
    Masanori Aikawa, Abhijeet R. Sonawane, Sarvesh Chelvanambi, Takaharu Asano, Arda Halu, Joan T. Matamalas, Sasha A. Singh, Shizuka Uchida, Elena Aïkawa, Àlex Arenas et al. · 2025 · Frontiers in Science
  13. The Inherited Hypercholesterolemias
    Wann Jia Loh, Gerald Francis Watts · 2022 · Endocrinology and Metabolism Clinics of North America
  14. Familial Hypercholesterolemia and Lipoprotein(a): A Gordian Knot in Cardiovascular Prevention
    Amalia Despoina Koutsogianni, Petros Spyridonas Adamidis, Fotios Barkas, Evangelos N. Liberopoulos, Ta‐Chen Su, Shizuya Yamashita, George L. Liamis, Manfredi Rizzo · 2022 · Metabolites
  15. Future directions for medicinal chemistry in the field of oligonucleotide therapeutics
    Jonathan Hall · 2023 · RNA
  16. The Link between Magnesium Supplements and Statin Medication in Dyslipidemic Patients
    Roxana Nartea, Brînduşa Ilinca Mitoiu, Ioana Adriana Ghiorghiu · 2023 · Current Issues in Molecular Biology
  17. RNA nanomedicine in liver diseases
    Anita K. Bakrania, Yulin Mo, Gang Zheng, Mamatha Bhat · 2023 · Hepatology
  18. Exploration of the Noncoding Genome for Human-Specific Therapeutic Targets—Recent Insights at Molecular and Cellular Level
    Wolfgang C. Poller, Susmita Sahoo, Roger J. Hajjar, Ulf Landmesser, Anna M. Krichevsky · 2023 · Cells
  19. Evolution and Outcomes of Premature Coronary Artery Disease
    Cara Lea Smith, Matthew E. Seigerman, Srinath Adusumalli, Jay S. Giri, Paul Nicolas Fiorilli, Daniel M. Kolansky, Taisei Kobayashi · 2021 · Current Cardiology Reports
  20. The year in cardiovascular medicine 2021: dyslipidaemia
    Lale S Tokgözoğlu, Carl E. Orringer, Henry N. Ginsberg, Alberico Luigi Catapano · 2021 · European Heart Journal
  21. Gene therapy for polygenic or complex diseases
    Tingting Wu, Yu Hu, Liang V. Tang · 2024 · Biomarker Research
  22. Lipoprotein (a): Underrecognized Risk with a Promising Future
    Matteo Manzato, R. Scott Wright, Allan S. Jaffe, Vlad C. Vasile · 2024 · Reviews in Cardiovascular Medicine
  23. Valvular calcification in chronic kidney disease: new insights from recent clinical and preclinical studies
    Lucie Hénaut, Alexandre Candellier, Sharon Huish, Nervana Issa, Smeeta Sinha, Ziad A. Massy · 2024 · Clinical Kidney Journal
  24. Atherosclerotic cardiovascular disease risk and elevated lipoprotein(a) among young adults with myocardial infarction: The Partners YOUNG-MI Registry
    Adam N. Berman, David W. Biery, Avinainder Singh, Wanda Y. Wu, Sanjay Divakaran, Ersilia M. DeFilippis, Jon Mark Hainer, Michael Joseph Blaha, Christopher Paul Cannon, Donna M. Polk et al. · 2020 · European Journal of Preventive Cardiology
  25. Role of Increased Lipoprotein (a) in Retinal Vein Occlusion: A Systematic Review and Meta-analysis
    Francesco Paciullo, David Giannandrea, Gianni Virgili, Carlo Cagini, Paolo Gresele · 2021 · TH Open
  26. Oxidized phospholipids on apolipoprotein B-100 versus plasminogen and risk of coronary heart disease in the PROCARDIS study
    Robert Clarke, Imen Hammami, Paul Sherliker, Elsa Valdés‐Márquez, Hugh C Watkins, Michael Hill, Xiaohong Yang, Sotirios Tsimikas, Jemma C. Hopewell · 2022 · Atherosclerosis
  27. Characteristics and lipid lowering treatment patterns in patients tested for lipoprotein(a): A real-world US study
    Xingdi Hu, Joaquim Rosado Cristino, Raju Gautam, Rina K Mehta, Diana T. Amari, Ji Haeng Heo, Siwei Wang, Nathan D. Wong · 2023 · American Journal of Preventive Cardiology
  28. Approach to the Patient With a Suboptimal Statin Response: Causes and Algorithm for Clinical Management
    Lufan Sun, Anna T Wolska, Marcelo J. Amar, Rafael Zubirán, Alan Thomas Remaley · 2023 · The Journal of Clinical Endocrinology & Metabolism
  29. Association of Lipoprotein(a) With Changes in Coronary Atherosclerosis in Patients Treated With Alirocumab
    Konstantinos C. Koskinas, Jonas Dominik Häner, Yasushi Ueki, Tatsuhiko Otsuka, Jacob Lønborg, Hiroki Shibutani, Ryota Kakizaki, Christoph A. Kaiser, Robert‐Jan van Geuns, Anna S. Ondracek et al. · 2024 · Circulation Cardiovascular Imaging
  30. Study of lipoprotein(a) and its impact on atherosclerotic cardiovascular disease: Design and rationale of the Mass General Brigham Lp(a) Registry
    Adam N. Berman, David W. Biery, Curtis R. Ginder, Olivia L. Hulme, Daniel P. Marcusa, Orly Leiva, Wanda Y. Wu, Avinainder Singh, Sanjay Divakaran, Jon Mark Hainer et al. · 2020 · Clinical Cardiology
  31. Relation of First and Total Recurrent Atherosclerotic Cardiovascular Disease Events to Increased Lipoprotein(a) Levels Among Statin Treated Adults With Cardiovascular Disease
    Nathan D. Wong, Yanglu Zhao, Jennifer Sung, Auris Browne · 2021 · The American Journal of Cardiology
  32. Effect of Weight Loss by Low-Calorie Diet on Cardiovascular Health in Type 2 Diabetes: An Interventional Cohort Study
    Shaden Melhem, Sarah Steven, Roy Taylor, Ahmad H. Al-Mrabeh · 2021 · Nutrients
  33. Discordance analyses comparing LDL cholesterol, Non-HDL cholesterol, and apolipoprotein B for cardiovascular risk estimation
    Camilla Ditlev Lindhardt Johannesen, Martin Bødtker Mortensen, Børge Grønne Nordestgaard, Anne Langsted · 2025 · Atherosclerosis
  34. Current Clinical Trials for Treating Elevated Lipoprotein(a)
    Chris De Los Reyes, Rishi Raj Rikhi, Sean Doherty, Sebastian Hernandez, Saeid Mirzai, Michael David Shapiro, Michael Christof, Scott W. McIntosh, Nathan D. Wong, Robert Block · 2025 · Current Cardiovascular Risk Reports
  35. Dyslipidemia in childhood and adolescence: from screening to management
    Elizabeth Yeung, Stephen R. Daniels, Sonali S. Patel · 2020 · Current Opinion in Endocrinology Diabetes and Obesity
  36. Importance of Coagulation Factors as Critical Components of Premature Cardiovascular Disease in Familial Hypercholesterolemia
    Uffe Ravnskov, Michel de Lorgeril, Malcolm E Kendrick, David M. Diamond · 2022 · International Journal of Molecular Sciences
  37. New Horizons: Revival of Lipoprotein (a) as a Risk Factor for Cardiovascular Disease
    Paul John Nestel, Wann Jia Loh, Natalie C. Ward, Gerald Francis Watts · 2022 · The Journal of Clinical Endocrinology & Metabolism
  38. Cellular Senescence, Aging and Non-Aging Processes in Calcified Aortic Valve Stenosis: From Bench-Side to Bedside
    Andrea Molnár, Dorottya Tímea Pásztor, Béla Péter Merkely · 2022 · Cells
  39. Recent lipoprotein(a) trials
    Trent L. Wei, Leslie Cho · 2022 · Current Opinion in Lipidology
  40. Optimizing Dietary Patterns and Lifestyle to Reduce Atherosclerotic Cardiovascular Risk Among South Asian Individuals
    Sri Charitha Koneru, Geeta Sikand, Anandita Agarwala · 2023 · The American Journal of Cardiology
  41. Present and Future of Dyslipidaemia Treatment—A Review
    Iveta Merćep, Andro Vujević, Dominik Strikić, Ivana Barbić Radman, Ivan Pećin, Željko Reiner · 2023 · Journal of Clinical Medicine
  42. Contribution of Lipoprotein(a) to Polygenic Risk Prediction of Coronary Artery Disease: A Prospective UK Biobank Analysis
    Hasanga D. Manikpurage, Audrey Paulin, Arnaud S. Girard, Aïda Eslami, Patrick Mathieu, Sébastien Thériault, Benoît J. Arsenault · 2023 · Circulation Genomic and Precision Medicine
  43. Major Facilitator Superfamily Domain Containing 5 Inhibition Reduces Lipoprotein(a) Uptake and Calcification in Valvular Heart Disease
    Maximillian A. Rogers, Francesca Bartoli‐Leonard, Kang H. Zheng, Aeron Small, Hao Yu Chen, Cassandra L. Clift, Takaharu Asano, Shiori Kuraoka, Mark C. Blaser, Katelyn A. Perez et al. · 2023 · Circulation
  44. Association of Lipoprotein(a) With Severe Degenerative Aortic Valve Stenosis
    Ah‐Ram Kim, Jung‐Min Ahn, Do‐Yoon Kang, Tae Joon Jun, Byung Joo Sun, Ho Jin Kim, Joon Bum Kim, Dae‐Hee Kim, Duk‐Woo Park, Young‐Hak Kim et al. · 2024 · JACC Asia
  45. Lipid-Lowering Biotechnological Drugs: from Monoclonal Antibodies to Antisense Therapies—a Clinical Perspective
    Xiaoming Jia, Jing Liu, Anurag Mehta, Christie Mitchell Ballantyne, Salim S. Virani · 2020 · Cardiovascular Drugs and Therapy
  46. Elevated lipoprotein(a) and risk of coronary heart disease according to different lipid profiles in the general Chinese community population: the CHCN-BTH study
    Chunyue Guo, Han Cao, Guangliang Shan, Wei Zhao, Han Zhang, Kaijun Niu, Ze Qin Cui, Naijun Tang, Kuo Liu, Li Pan et al. · 2021 · Annals of Translational Medicine
  47. Influence of lipid-lowering drugs on inflammation: what is yet to be done?
    Sabina Ugovšek, Janja Zupan, Andreja Rehberger Likozar, Miran Šebeštjen · 2021 · Archives of Medical Science
  48. The relationship between lipoprotein(a) and cardiovascular events in acute coronary syndrome patients with and without chronic kidney disease
    Qing Li, Yinong Chen, Luyao Yu, Longyang Zhu, Zhe Wang, Siqi Jiao, Chao Wu, Yimin Tu, Yaxin Wu, Ziyu Guo et al. · 2022 · Atherosclerosis
  49. New Approaches for the Prevention and Treatment of Cardiovascular Disease: Focus on Lipoproteins and Inflammation
    Aliza Hussain, Christie Mitchell Ballantyne · 2020 · Annual Review of Medicine
  50. The Prevalence of Elevated Lipoprotein(a) in Patients Presenting With Coronary Artery Disease
    Hannah H. Oo, Julian Giovannucci, Richard Charles O’Brien, David L. Hare · 2020 · Heart Lung and Circulation
  51. The Clinical Importance of Differentiating Monogenic Familial Hypercholesterolemia from Polygenic Hypercholesterolemia
    Fistra Janrio Tandirerung · 2022 · Current Cardiology Reports
  52. Relationship Between Lipoprotein(a), Renal Function Indicators, and Chronic Kidney Disease: Evidence From a Large Prospective Cohort Study
    Yingxin Liu, Ruoting Wang, Shuai Li, Changfa Zhang, Gregory Y.H. Lip, Lehana Thabane, Guowei Li · 2024 · JMIR Public Health and Surveillance
  53. Flaxseed (Linum Usitatissimum L.) Supplementation in Patients Undergoing Lipoprotein Apheresis for Severe Hyperlipidemia—A Pilot Study
    Dominika Kanikowska, Katarzyna Korybalska, Agnieszka Mickiewicz, Rafał Rutkowski, Agnieszka Kuchta, Maki Sato, Ewelina Kreft, Marcin Fijałkowski, Marcin Gruchała, Maciej Jankowski et al. · 2020 · Nutrients
  54. The interconnection between lipoprotein(a), lipoprotein(a) cholesterol and true LDL-cholesterol in the diagnosis of familial hypercholesterolemia
    Calvin Yeang, Peter Willeit, Sotirios Tsimikas · 2020 · Current Opinion in Lipidology
  55. New Insights Into the Regulation of Lipoprotein Metabolism by PCSK9: Lessons From Stable Isotope Tracer Studies in Human Subjects
    Qidi Ying, Dick C. Chan, Gerald Francis Watts · 2021 · Frontiers in Physiology
  56. Association between lipoprotein (a) and heart failure with reduced ejection fraction development
    Baoquan Wu, Zhiling Zhang, Juan Long, Hanjun Zhao, Fanfang Zeng · 2021 · Journal of Clinical Laboratory Analysis
  57. The association of lipoprotein(a) and intraplaque neovascularization in patients with carotid stenosis: a retrospective study
    Shuang Xia, Weida Qiu, Anping Cai, Bo Kong, Lan Xu, Zejia Wu, Liwen Li · 2021 · BMC Cardiovascular Disorders
  58. Metabolic disorders affecting the liver and heart: Therapeutic efficacy of miRNA-based therapies?
    Lucia La Sala, Valentina Carlini, Caterina Conte, Maria Belen Macas-Granizo, Elham Afzalpour, Jimmy Martín-Delgado, Marco D’Anzeo, Roberto F.E. Pedretti, Angelo Naselli, Antonio Ettore Pontiroli et al. · 2024 · Pharmacological Research
  59. Lp(a)-Lowering Agents in Development: A New Era in Tackling the Burden of Cardiovascular Risk?
    Niki Katsiki, Michal Vrablı́k, Maciej Banach, Ioanna Gouni‐Berthold · 2025 · Pharmaceuticals
  60. Residual risk in atherosclerotic cardiovascular disease after statin therapy: Clinical mechanisms and management strategies
    Sze-Hua Tan, Jia-Lin Wu, Shu-Xiong Zhuo, Yi Zhang, Miao Wang · 2026 · World Journal of Cardiology
  61. Lipoprotein(a) and Cardiovascular Outcomes after Revascularization of Carotid and Lower Limbs Arteries
    Ежов Марат Владиславович, Narek A. Tmoyan, Olga I. Afanasieva, Marina I. Afanasieva, Sergei N. Pokrovsky · 2021 · Biomolecules
  62. PCSK9 Inhibition and Oxidized Phospholipids
    Harpreet Singh Bhatia, Calvin Yeang, Amos Baruch, Xiaohong Yang, Erik S.G. Stroes, Sotirios Tsimikas · 2021 · Journal of the American College of Cardiology
  63. Lipoprotein(a) as Part of the Diagnosis of Clinical Familial Hypercholesterolemia
    Anne Langsted, Børge Grønne Nordestgaard · 2022 · Current Atherosclerosis Reports
  64. Lipid profile and lipoprotein(a) testing
    Klaus Georg Parhofer, Ulrich Laufs · 2023 · Deutsches Ärzteblatt international
  65. Management of dyslipidemia in coronary artery disease: the present and the future
    Kyriakos S. Dimitriadis, Panagiotis Theofilis, Panagιotis Iliakis, Nikolaos Pyrpyris, Eirini Dri, Athanasios Sakalidis, Στέργιος Σουλαϊδόπουλος, Panagiotis Tsioufis, Christos Fragkoulis, Christina A. Chrysohoou et al. · 2024 · Coronary Artery Disease
  66. Lipoprotein(a) and its impact on cardiovascular disease – the Polish perspective: design and first results of the Zabrze-Lipoprotein(a) Registry
    Krzysztof Dyrbuś, Zofia Mędrala, Karolina Konsek, Alicja Nowowiejska‐Wiewióra, Przemysław Trzeciak, Michał Skrzypek, Daniel Cieśla, Maciej Banach, Mariusz Gąsior · 2024 · Archives of Medical Science
  67. Development and multinational validation of an algorithmic strategy for high Lp(a) screening
    Arya Aminorroaya, Lovedeep Singh Dhingra, Evangelos K. Oikonomou, Seyedmohammad Saadatagah, Phyllis Thangaraj, Sumukh Vasisht Shankar, Erica Sarah Spatz, Rohan Khera · 2024 · Nature Cardiovascular Research
  68. Non-coronary atherosclerotic cardiovascular disease in patients with familial hypercholesterolaemia
    Panagiotis G. Anagnostis, Konstantina Vaitsi, Gesthimani Mintziori, Dimitrios G. Goulis, Dimitri P. Mikhailidis · 2020 · Current Medical Research and Opinion
  69. Measuring lipoprotein(a): do it without ifs and buts
    Florian Kronenberg · 2021 · European Journal of Preventive Cardiology
  70. Lipoprotein(a), Residual Cardiovascular Risk, and the Search for Targeted Therapy
    Michael Joseph Blaha, Harpreet Singh Bhatia · 2024 · Journal of the American College of Cardiology
  71. Elevated lipoprotein(a) levels as an independent predictor of long-term recurrent events in patients with acute coronary syndrome: an observational, retrospective cohort study
    Si-qi Yang, Han-xiong Liu, Xiu-qiong Yu, Lin Tong, Xu Chen, Ling-yao Qi, Cai-yan Cui, Lian-chao Cheng, Lin Cai · 2022 · Coronary Artery Disease
  72. Familial Hypercholesterolemia and Lipoprotein(a): Two Partners in Crime?
    Rodrigo Alonso K, Rosa Argüeso, Pilar Álvarez-Baños, Ovidio Muñiz-Grijalvo, José Luis Díaz-Díaz, Pedro Mata · 2022 · Current Atherosclerosis Reports
  73. Effect of Different Types and Dosages of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors on Lipoprotein(a) Levels: A Network Meta-analysis
    Zongliang Yu, Lanqing Hu, Changxin Sun, Zeping Wang, Xiaonan Zhang, Min Wu, Longtao Liu · 2023 · Journal of Cardiovascular Pharmacology
  74. Relationship between lipoprotein(a) levels, cardiovascular outcomes and death in patients with chronic kidney disease: a systematic review of prospective studies
    Leandro Barbagelata, Walter M. Masson, Pablo Corral, Augusto Lavalle Cobo, Juan Patricio Nogueira, Guillermo Rosa Diez · 2023 · Journal of Nephrology
  75. Lipoprotein(a) in Familial Hypercholesterolemia
    Erin O. Jacob, Adam D. McIntyre, Jian Wang, Robert Alexander Hegele · 2023 · CJC Open
  76. Measuring Lp(a) particles with a novel isoform-insensitive immunoassay illustrates efficacy of muvalaplin
    Craig Swearingen, John H. Sloan, Grace M. Rhodes, Robert W. Siegel, Nicoletta Bivi, Yuewei Qian, Robert J. Konrad, Michael B. Boffa, Marlys L. Koschinsky, John Henry Krege et al. · 2024 · Journal of Lipid Research
  77. Lipoprotein (a) as a treatment target for cardiovascular disease prevention and related therapeutic strategies: a critical overview
    Ioannis Parthymos, Michael S. Kostapanos, Dimitri P. Mikhailidis, Matilda Florentin · 2021 · European Journal of Preventive Cardiology
  78. RNA-targeted therapeutics in cardiovascular disease: the time is now
    Konstantin Alexander Krychtiuk, Daniel James Rader, Christopher Bull Granger · 2022 · European Heart Journal - Cardiovascular Pharmacotherapy
  79. Genetic proxies for PCSK9 inhibition associate with lipoprotein(a): Effects on coronary artery disease and ischemic stroke
    Gian Marco De Marchis, Tolga Daniel Dittrich, Rainer Malik, Annaelle V. Zietz, Lilian F. Kriemler, Brian A. Ference, Martin Dichgans, Marios K. Georgakis · 2022 · Atherosclerosis
  80. Antisense lipoprotein[a] therapy: State-of-the-art and future perspectives
    Giuseppe Lippi, Emmanuel J. Favaloro, Fabián Sanchis‐Gomar · 2020 · European Journal of Internal Medicine
  81. Novel RNA-Based Therapies in the Management of Dyslipidemias
    Constantine E. Kosmas, Maria D. Bousvarou, Donatos Tsamoulis, Maria Gianniou, Evangelia J. Papakonstantinou, Lοukianos S. Rallidis · 2025 · International Journal of Molecular Sciences
  82. Impact of Lipoprotein(a) concentrations on long-term cardiovascular outcomes in patients undergoing percutaneous coronary intervention: A large cohort study
    Kongyong Cui, Dong Yin, Cheng‐Gang Zhu, Sheng Yuan, Shaoyu Wu, Lei Feng, Kefei Dou · 2022 · Nutrition Metabolism and Cardiovascular Diseases
  83. Preclinical Toxicological Assessment of A Novel siRNA, SLN360, Targeting Elevated Lipoprotein (a) in Cardiovascular Disease
    David A. Rider, Simon Chivers, Julia Aretz, Mona Eisermann, Kathrin Löffler, Judith Hauptmann, Eliot Morrison, G. Campion · 2022 · Toxicological Sciences
  84. Lipoprotein Assessment in the twenty-first Century
    Diego Lucero, Anna T Wolska, Zahra Aligabi, Sarah E. Turecamo, Alan Thomas Remaley · 2022 · Endocrinology and Metabolism Clinics of North America
  85. Lipoprotein (a) as a Biomarker for Cardiovascular Diseases and Potential New Therapies to Mitigate Risk
    Debabrata Mukherjee, Steven E. Nissen · 2023 · Current Vascular Pharmacology
  86. Advances in Pharmacological Approaches for Managing Hypercholesterolemia: A Comprehensive Overview of Novel Treatments
    Andrea Mormone, Giovanni Tortorella, Francesca Esposito, Alfredo Caturano, Aldo Marrone, Domenico Cozzolino, Raffaele Galiero, Raffaele Marfella, Ferdinando Carlo Sasso, Luca Rinaldi · 2024 · Biomedicines
  87. Impact of High Lipoprotein(a) Levels on Delayed Wound Healing in Patients With Chronic Limb-Threatening Ischemia After Peripheral Endovascular Therapy
    Yusuke Tomoi, Mitsuyoshi Takahara, Yoshimitsu Soga, Taichi Hirano, Kazuki Tsunoda, Tomonori Katsuki, Kenji Andò · 2024 · Circulation Journal
  88. LP(a): The new marker of high cardiovascular risk
    Maurizio Rocco Averna, Angelo Baldassare Cefalu · 2024 · Nutrition Metabolism and Cardiovascular Diseases
  89. Why, how and in whom should we measure levels of lipoprotein(a): A review of the latest evidence and clinical implications
    Alexander C. Razavi, Harpreet Singh Bhatia, Roger S. Blumenthal, Michael D. Shapiro, Anurag Mehta · 2025 · Diabetes Obesity and Metabolism
  90. Antisense Oligonucleotide Therapy for Ophthalmic Conditions
    Kevin Ferenchak, Iris Deitch, Rachel M. Huckfeldt · 2021 · Seminars in Ophthalmology
  91. Targeting the Cholesterol Paradigm in the Risk Reduction for Atherosclerotic Cardiovascular Disease: Does the Mechanism of Action of Pharmacotherapy Matter for Clinical Outcomes?
    Ruihai Zhou, George A. Stouffer, Sidney C. Smith · 2021 · Journal of Cardiovascular Pharmacology and Therapeutics
  92. Genetics of Lipoprotein(a): Cardiovascular Disease and Future Therapy
    Anne Langsted, Børge Grønne Nordestgaard · 2021 · Current Atherosclerosis Reports
  93. The Role of Antisense Therapies Targeting Lipoprotein(a)
    Roda Plakogiannis, Maria A. Sorbera, Briann Fischetti, Mandy Chen · 2021 · Journal of Cardiovascular Pharmacology
  94. New Strategies for Lowering Low-Density Lipoprotein Cholesterol for Cardiovascular Disease Prevention
    Sean Paul Gaine, Renato Quispe, Jaideep Patel, Erin D. Michos · 2022 · Current Cardiovascular Risk Reports
  95. Integrated Assessment of Phase 2 Data on GalNAc 3 -Conjugated 2′- O -Methoxyethyl-Modified Antisense Oligonucleotides
    Brenda F. Baker, Shuting Xia, Wesley Partridge, T. Jesse Kwoh, Sotirios Tsimikas, Sanjay Bhanot, Richard S. Geary · 2022 · Nucleic Acid Therapeutics
  96. Lipoprotein(a) is associated with premature coronary artery disease: a meta-analysis
    Konstantinos A. Papathanasiou, Dimitrios Kazantzis, Lοukianos S. Rallidis · 2023 · Coronary Artery Disease
  97. Lipoprotein(a): Role in atherosclerosis and new treatment options
    Dragana Tomić-Naglić, Mia S. Manojlovic, Sladjana Pejaković, Kristina Stepanović, Jovana Prodanović · 2023 · Biomolecules and Biomedicine
  98. Lipoprotein(a) and Cardiovascular Disease: A Missing Link for Premature Atherosclerotic Heart Disease and/or Residual Risk.
    Helen Melita, Antonis A Manolis, Theodora A. Manolis, Antonis S. Manolis · 2022 · PubMed
  99. An evaluation of the pharmacokinetics of inclisiran in the treatment of atherosclerotic cardiovascular disease
    Tomlinson, Brian, Chow, Elaine, Chan, Paul, Lam, Christopher Wai Kei · 2021 · Expert Opinion on Drug Metabolism & Toxicology
  100. Association of Plasma Lipoprotein(a) With Major Adverse Cardiovascular Events in MASLD With or Without Advanced Liver Fibrosis
    Tie Xiao, Huihui Liu, Na Tian, Li‐You Lian, Kai‐Wen Miao, Yuting Li, Li‐Li Chen, Hai‐Yang Yuan, Mulong Du, Shanshan Wu et al. · 2025 · Liver International